Status:
UNKNOWN
Optimal Dosage of Ticagrelor in Korean Patients With AMI
Lead Sponsor:
Dong-A University
Conditions:
Acute Myocardial Infarction
Ticagrelor
Eligibility:
All Genders
20-75 years
Phase:
PHASE4
Brief Summary
East Asian patients will be required optimal dose of newer P2Y12 inhibitor (ticagrelor) to determine the safer treatment and better outcome. Whether low dose of ticagrelorI is more adequate for clinic...
Detailed Description
In recent years, newer oral P2Y12 receptor blocker (ticagrelor) has been strong recommendations for management of patients with AMI undergoing (PCI). This drug provided more profound inhibitory effect...
Eligibility Criteria
Inclusion
- Patients present with acute myocardial infarction undergoing PCI.
- Patients receiving ticagrelor; Male or female gender; Age 20-75 years.
- Patients provide written informed consent prior to enrollment.
Exclusion
- Low body weight (\<60kg).
- History of hemorrhagic stroke.
- History of upper gastrointestinal bleeding in recent 6 months.
- Bleeding tendency.
- Thrombocytopenia defined by platelet \< 100,000/ml.
- Anemia defined by hemoglobin \< 10 g/dl.
- Renal dysfunction defined as serum creatinine \> 2.5 mg/dl.
- Severe hepatic dysfunction defined as serum transaminase \> 3 times normal limit.
- Known severe chronic obstructive pulmonary disease or bradycardia (sick sinus syndrome (SSS) or high degree AV block without pacemaker protection).
- Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromycin.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05210595
Start Date
January 1 2022
End Date
December 31 2023
Last Update
January 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
DongA University Hospital
Busan, South Korea, 602-715